Pure Biologics Company Description

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases.

It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules.

The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use.

It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis; and provides contract research for pharmaceutical and biotechnology companies.

Pure Biologics S.A. was incorporated in 2010 and is headquartered in Wroclaw, Poland.

Pure Biologics S.A.

Country	Poland
Founded	2010
Industry	Biotechnology
Sector	Healthcare
Employees	51

Contact Details

Address: ul. Dunska 11 Wroclaw, 54-427 Poland
Phone	48 795 61 18 11
Website	purebiologics.com

Stock Details

Ticker Symbol	PUR
Exchange	Warsaw Stock Exchange
Fiscal Year	January - December
Reporting Currency	PLN
ISIN Number	PLPRBLG00010
SIC Code	2836

Key Executives

Name	Position
Dr. Filip Jelen M.B.A., Ph.D.	Co-founder and President of the Management Board
Romuald Apollo Harwas	Chief Financial Officer and Member of the Management Board
Dr. Pieter Spee	Chief Scientific Officer and Member of the Management Board
Martyna Koj	Director of the Company Office and Investor Relations Representative
Marta Rot	Head of Human Resources
Przemyslaw Dudek	Head of Information Technology
Dr. Ewelina Swiderek Ph.D.	Head of Project Management
Maciej Mazurek M.B.A.	Director of Science and Innovation